Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Phase 1 Completed 46 enrolled Merck Sharp & Dohme LLC Ariad Pharmaceuticals · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of ridaforolimus in patients with refractory or recurrent malignancies, including myeloma and lymphoma.

Timeline

Start: 2003-04
Primary completion: 2005-10
Completion: 2005-10

Publications

Background Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15;15(4):1428-34. doi: 10.1158/1078-0432.CCR-08-2076.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ridaforolimus	Small molecule	6.25 mg	Intravenous
Subject	ridaforolimus	Small molecule	12.5 mg	Intravenous
Subject	ridaforolimus	Small molecule	25 mg	Intravenous
Subject	ridaforolimus	Small molecule	50 mg	Intravenous
Subject	ridaforolimus	Small molecule	75 mg	Intravenous
Subject	ridaforolimus	Small molecule	100 mg	Intravenous

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Summary

Timeline

Publications

Drugs

Indications